Lantheus Holdings

November 17, 2020November 17, 2020

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

News

An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug ... Read more

October 6, 2020October 6, 2020

Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent

News

Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new ... Read more